Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy

Leukemia

Volumn 17, Issue 3, 2003, Pages 590-603

  Chang, F ^a   Lee, J T ^a   Navolanic, P M ^a   Steelman, L S ^a   Shelton, J G ^a   Blalock, W L ^b   Franklin, R A ^a   McCubrey, J A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Akt; Apoptosis; Cell cycle; Inhibition; PI3K; PTEN; Targeted therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; AG 957; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; L 778123; LONAFARNIB; NSC 654705; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; QUERCETIN; RAPAMYCIN; TIPIFARNIB; TYRPHOSTIN; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR SPACE; GENE EXPRESSION; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037352170     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402824     Document Type: Review

References (168)

1. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13: 1109-1166.
2. Franklin RA, McCubrey JA. Kinases: positive and negative regulators of apoptosis. Leukemia 2000; 14: 2019-2034.
3. White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia 2001; 15: 1011-1021.
4. McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F et al. Synergistic effects of PI3K/Akt on abrogation of cytokine-dependency induced by oncogenic Raf. Adv Enzyme Regul 2001; 41: 289-323.
5. McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F et al. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 2001; 25: 375-393.
6. McCubrey JA, Blalock WL, Chang F, Steelman LS, Pohnert SC, Navolanic PM et al. Signal transduction pathways: cytokine model. In: Blagosklonny M. (ed). Cell Cycle Checkpoints and Cancer. Austin, TX: Landes Bioscience Press, 2001, pp 17-51.
7. McCubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000; 14: 9-21.
8. McCubrey JA, Blalock WL, Saleh O, Pearce M, Burrows C, Steelman LS et al. Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells. Leukemia 2001; 15: 1203-1216.
9. Srinivasa SP, Doshi PD. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002; 16: 244-253.
10. Lee Jr JT, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002; 16: 486-507.
11. Lee Jr JT, McCubrey JA. Targeting the Raf kinase cascade in cancer therapy-novel molecular targets and therapeutic strategies. Expert Opin Ther Targets 2002 6: 659-678.
12. Jucker M, Sudel K, Horn S, Sickel M, Wegner W, Fiedler W et al. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002; 16: 894-901.
13. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999; 59: 2891-2897.
14. Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 2001; 3: 304-312.
15. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001; 386: 293-301.
16. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999; 24: 64-69.
17. Martinez-Lorenzo MJ, Anel A, Monleon I, Sierra JJ, Pineiro A, Naval J et al. Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int J Biochem Cell Biol 2000; 32: 435-445.
18. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395.
19. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3′kinase: one of the effectors of Ras. Philos Trans Roy Soc London Ser B: Biol Sci 1996; 351: 225-231.
20. Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001; 2: 760-768.
21. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997; 22: 267-272.
22. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signall 1998; 10: 233-239.
23. Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000; 103: 931-943.
24. Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci 2002; 27: 426-432.
25. Chan TO, Rodeck U, Chan AM, Kimmelman AC, Rittenhouse SE, Panayotou G et al. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 2002; 1: 181-191.
26. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998; 273: 24052-24056.
27. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide signaling. Biochim Biophys Acta 2000; 1470: M21-M35.
28. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphomositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998; 95: 15587-15591.
29. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 19981; 92: 3410-3415.
30. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM et al. 5′Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 2000; 20: 6860-6871.
31. Muraille E, Pesesse X, Kuntz C, Erneux C. Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement in SHIP-2 in negative signaling of B-cells. Biochem J 1999; 342: 697-705.
32. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998; 227: 43-55.
33. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997; 13: 261-291.
34. Peter M. The regulation of cyclin-dependent kinase inhibitors (CKIs). Prog Cell Cycle Res 1997; 3: 99-108.
35. Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgette J, Abbound HE. PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. Am J Physiol 1997; 273: F931-F938.
36. 1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-3511.
37. Gille H, Downward J. Multiple ras effector pathways contribute to G1 cell cycle progression. J Biol Chem 1999; 274: 22033-22040.
38. Kip1 . Nature 2000; 404: 782-787.
39. Muise-Helmericks RC, Grimers HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998; 273: 29864-29872.
40. Kip1 gene expression. J Biol Chem 2002; 276: 35636-35643.
41. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
42. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6: 387-400.
43. Sherr CJ, Roberts MJ. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
44. Rank KB, Evans DB, Sharma SK. The N-terminal domains of cyclin-dependent kinase inhibitory proteins block the phosphorylation of cdk2/cyclin E by the CDK-activating kinase. Biochem Biophys Res Commun 2000; 271: 469-473.
45. Shimizu T, Takahashi N, Tachibana K, Takeda K. Complex regulation of CDK2 and G1 arrest during neuronal differentiation of human prostatic cancer TSU-Prl cells by staurosporine. Anticancer Res 2001; 21: 893-898.
46. Lawlor MA, Rotwein P. Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol Cell Biol 2000; 23: 8983-8995.
47. WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2000; 60: 5390-5394.
48. Schönherr E, Levkau B, Schaefer L, Kresse H, Walsh K. Decorin-mediated signal transduction in endothelial cells. J Biol Chem 2001; 276: 40687-40692.
49. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3: 245-252.
50. Cip/WAF1 and promotes cell survival. J Biol Chem 2002; 277: 11352-11361.
51. Cip1 degradation. J Biol Chem 2002; 277: 9684-9689.
52. Cip1 regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001; 21: 5644-5657.
53. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
54. Flores-Rozas H, Kelman Z, Dean FB, Pan ZQ, Harper JW, Elledge SJ et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci USA 1994; 91: 8655-8659.
55. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996; 227: 564-569.
56. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
57. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998; 273: 13150-13156.
58. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
59. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997; 17: 355-363.
60. Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 2000; 5: 403-410.
61. Touitou R, Richardson J, Bose S, Nakanishi M, Rivett J, Allday MJ. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. EMBO J 2001; 20: 2367-2375.
62. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
63. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
64. Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 2001; 20: 4353-4364.
65. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995; 268: 100-102.
66. Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000; 14: 142-146.
67. Choudhury GG, Kim YS, Simon M, Wozney J, Harris S, Choudhury GN et al. Bone morphogenetic protein 2 inhibits platelet-derived growth factor-induced c-fos gene transcription and DNA synthesis in mesangial cells. Involvement of mitogen-activated protein kinase. J Biol Chem 1999; 274: 10897-10902.
68. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
69. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136-1144.
70. Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-1152.
71. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K et al. PKB/Akt phosphorylates, p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-1160.
72. Beg AA, Baldwin Jr AS. Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor. Oncogene 1994; 9: 1487-1492.
73. Beg AA, Finco TS, Nantermet PV, Baldwin Jr AS. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 1993; 13: 3301-3310.
74. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782-784.
75. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-787.
76. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-789.
77. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-576.
78. Beauparlant P, Kwan I, Bitar R, Chou P, Koromilas AE, Sonenberg N et al. Disruption of I kappa B alpha regulation by antisense RNA expression leads to malignant transformation. Oncogene 1994; 9: 3189-3197.
79. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20: 2687-2695.
80. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-387.
81. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96: 9136-9141.
82. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923-5929.
83. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000; 12: 85-98.
84. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
85. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000; 20: 1626-1638.
86. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
87. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
88. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996; 56: 1851-1854.
89. Lau QC, Brusselbach S, Muller R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 1998; 16: 1899-1902.
90. Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T et al. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med 1998; 187: 1995-2007.
91. Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R et al. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res 1999; 59: 2815-2819.
92. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19: 7203-7215.
93. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine-dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12: 1903-1929.
94. McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F et al. Effects of deregulated Raf and MEK1 expression on the cytokine-dependency of hematopoietic cells. Adv Enzyme Regul 2000; 40: 305-337.
95. Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein-Oppenheimer C et al. Synergy between Raf and BCL2 in abrogating the cytokine-dependency of hematopoietic cells. Leukemia 2000; 14: 1060-1079.
96. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M et al. Differential abilities of the Raf family of protein of kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000: 14: 642-656.
97. Waf1 and p53 requires c-raf-1. Cancer Res 1995; 55: 4623-4626.
98. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI3K and PKB. Nature 1997; 385: 544-548.
99. Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J Biol Chem 1998; 273: 30419-30426.
100. von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR et al. Apoptosis suppression by Raf-1 and MEK1 requires MEK and phosphatidylinositol 3-kinase dependent signals. Mol Cell Biol 2001; 21: 2324-2336.
101. Yuryev A, Ono M, Goff SA, Macaluso F, Wennogle LP. Isoform-specific localization of A-RAF in mitochondria. Mol Cell Biol 2000; 20: 4870-4878.
102. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
103. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. P70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule Bad. Proc Natl Acad Sci USA 2001; 98: 9666-9670.
104. Fang X, Yu S, Eder A, Mao M, Bast Jr RC, Boyd D et al. Regulation of BAD phosphorylation at serine 112 by the Rasmitogen-activated protein kinase pathway. Oncogene 1999; 18: 6635-6640.
105. Virdee K, Parone PA, Tolkovsky AM. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol 2000; 10: 1151-1154.
106. Chang F, Steelman LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 2002; 1: 220-226.
107. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas SH, Lam EWF et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27Kip1. Mol Cell Biol 2000; 20: 9138-9148.
108. Cip. Mol Cell Biol 1997; 17: 5598-5611.
109. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/Cdk complexes. Genes Dev 1997; 11: 663-677.
110. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H et al. A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene 2000; 19: 526-536.
111. Blalock WL, Moye PW, Chang F, Pearce M, Steelman LS, McMahon M et al. Combined effects of aberrant MEK1 activity and BCL-2 overexpression on relieving the cytokine-dependency of human and murine hematopoietic cells. Leukemia 2000; 14: 1080-1096.
112. Blalock WL, Pearce M, Chang F, Lee J, Pohnert SC, Burrows C et al. Effects of inducible MEK1 activation on the cytokine-dependency of lymphoid cells. Leukemia 2001; 15: 794-807.
113. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286: 1741-1744.
114. Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 2000; 275: 27354-27359.
115. Reusch JP, Zimmermann S, Schaefer M, Paul M, Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001; 276: 7644-7655.
116. Rommel C, Clarke BA, Zimmermann S, Nuñez L, Rossamn R, Reid K et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286: 1738-1741.
117. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt cross-talk. J Biol Chem 2002; 277: 31099-31106.
118. Mizuno H, Nishida E. The ERK MAP kinase pathway mediates induction of SGK (serum- and glucocorticoid-inducible kinse) by growth factors. Genes Cells 2001; 6: 261-268.
119. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI3-kinase-stimulated signaling pathway. EMBO J 1999; 18: 3024-3033.
120. Kobayashi T, Deak M, Morrice N, Cohen P. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem J 1999; 344: 189-197.
121. Gonzalez-Robayna IJ, Falender AE, Ochsner S, Firestone GL, Richards JS. Follicle-stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-induced kinase (SGK): evidence for a kinase-independent signaling by FSH in granulosa cells. Mol Endocrinol 2000; 14: 1283-1300.
122. Prasad N, Topping RS, Zhou D, Decker SJ. Oxidative stress and vanadate induce tyrosine phosphorylation of phosphoinositide-dependent kinase 1 (PDK1). Biochemistry 1998; 39: 6929-6935.
123. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
124. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
125. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 1998; 143: 1375-1383.
126. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
127. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998; 95: 13513-13518.
128. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM et al. 5′Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 2000; 20: 6860-6871.
129. Muraille E, Pesesse X, Kuntz C, Erneux C. Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement in SHIP-2 in negative signaling of B-cells. Biochem J 1999; 342: 697-705.
130. Baserga R, Morrione A. Differentiation and malignant transformation: two roads diverged in a wood. J Cell Biochem 1999; 32: (Suppl) 68-75.
131. Suzuki J, Kaziro Y, Koide H. An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-1. Oncogene 1997; 15: 1689-1697.
132. McIlroy J, Chen D, Wjasow C, Michaeli T, Backer JM. Specific activation of p85-p110 phosphatidylinositol 3′-kinase stimulates DNA synthesis by Ras- and p70 S6 kinase-dependent pathways. Mol Cell Biol. 1997; 17: 248-255.
133. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3′kinase: one of the effectors of Ras. Philos Trans Roy Soc London Ser B: Biol Sci 1996; 351: 225-231.
134. Dahia PL, Aquiar RC, Alberta J, Kum JB, Caron S, Sill H et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanism in haematological malignancies. Hum Mol Genet 1999; 8: 185-193.
135. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 1998; 92: 3410-3415.
136. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S et al. Increased Akt activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip-1 expression. J Biol Chem 2000; 275: 24500-24505.
137. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84: 5034-5037.
138. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA. 1992; 89: 9267-9271.
139. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK et al. Amplification of AKT2 in human pancreatic cells and inhibiton of AKT2 expression and tumorigenicity by anti-sense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-3641.
140. Scheid MP, Huber M, Damen JE, Hughes M, Kang V, Neilsen P et al. Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for PKB activation: phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser473, studies using cells from SHIP-/-knockout mice. J Biol Chem 2002; 277: 9027-9035.
141. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351(Part 1): 95-105.
142. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
143. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993; 296(Part 2): 297-301.
144. Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M et al. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 2000; 43: 3045-3051.
145. Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol 2002; 63: 689-692.
146. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58: 373-395.
147. Ferrari S, Pearson RB, Siegmann M, Kozma SC, Thomas G. The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. J Biol Chem 1993; 268: 16091-16094.
148. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-736.
149. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-3641.
150. Liu X, Shi Y, Han EK, Chen Z, Rosenberg SH, Giranda VL et al. Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia 2001; 3: 278-286.
151. Flynn P, Wongdagger M, Zavar M, Dean NM, Stokoe D. Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol 2000; 10: 1439-1442.
152. Shaikenov TE, Adekenov SM, Williams RM, Prashad N, Baker FL, Madden TL et al. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase. Oncol Rep 2001; 8: 173-179.
153. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-1074.
154. Johnston SR. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2001; 2: 18-26.
155. Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20(1): 139-148.
156. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 4: 451-460.
157. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51: 1744-1748.
158. Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF et al. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 2001; 92: 1265-1271.
159. Morse MA. Technology evaluation: ISIS-2503, Isis Pharmaceuticals. Curr Opin Mol Ther 2001; 3: 589-594.
160. Feig LA, Cooper GM. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol Cell Biol 1988; 8: 3235-3243.
161. Feig LA. Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases. Nat Cell Biol 1999; 1: E25-E27.
162. Akagi T, Murata K, Shishido T, Hanafusa H. v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras. Mol Cell Biol 2002; 22: 7015-7023.
163. Fiordalisi JJ, Holly SP, Johnson II RL, Parise LV, Cox AD. A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion. J Biol Chem 2002; 277: 10813-10823.
164. Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, Kataoka Y et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 2002; 277: 8076-8082.
165. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999; 19: 1346-1358.
166. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to Paclitaxel. J Biol Chem 2002; 277: 33490-33500.
167. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM et al. 5′ Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 2000; 20: 6860-6871.
168. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-4805.